Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission.
In: Journal of Infectious Diseases, Jg. 181 (2000), Heft 1, S. 99-106
Online
academicJournal
Zugriff:
Human immunodeficiency virus (HIV) levels in cervicovaginal lavage (CVL) and plasma samples were evaluated in relation to perinatal transmission in a randomized placebo-controlled trial of brief antenatal zidovudine treatment. Samples were collected at 38 weeks' gestation from 310 women and more frequently from a subset of 74 women. At 38 weeks, after a 2-week treatment period, CVL HIV-1 was quantifiable in 23% and 52% of samples in the zidovudine and placebo groups, respectively (P<.001). The perinatal transmission rate was 28.7% among women with quantifiable CVL HIV-1 and high plasma virus levels (>10,000 copies/mL) and 1% among women without quantifiable CVL HIV-1 and with low plasma virus levels (P<.001). A 1-log increase in plasma HIV-1 increased the transmission odds 1.8 and 6.1 times (95% confidence interval, 0.9-3.5 vs. 2.4-15.4) for women with and without quantifiable CVL HIV-1, respectively (P=.03). CVL HIV-1 is an independent risk factor for perinatal HIV-1 transmission. Copyright © 2000 The University of Chicago [ABSTRACT FROM AUTHOR]
Titel: |
Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission.
|
---|---|
Autor/in / Beteiligte Person: | Chuachoowong, R ; Shaffer, N ; Siriwasin, W ; Chaisilwattana, P ; Young, NL ; Mock, PA ; Chearskul, S ; Waranawat, N ; Chaowanachan, T ; Karon, J ; Simonds, RJ ; Mastro, TD ; Bangkok Collaborative Perinatal HIV Transmission Study Group |
Link: | |
Zeitschrift: | Journal of Infectious Diseases, Jg. 181 (2000), Heft 1, S. 99-106 |
Veröffentlichung: | 2000 |
Medientyp: | academicJournal |
ISSN: | 0022-1899 (print) |
DOI: | 10.1086/315179 |
Sonstiges: |
|